Trials / Unknown
UnknownNCT05426850
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
Circulating Tumor DNA-based Minimal Residual Disease (MRD) Assessment in Local Advanced Esophageal Squamous Cell Carcinoma Treated by Definitive Concurrent Chemoradiotherapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
Conditions
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2022-12-31
- Completion
- 2024-12-01
- First posted
- 2022-06-22
- Last updated
- 2022-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05426850. Inclusion in this directory is not an endorsement.